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Nasopharyngeal carcinoma: an EBV-associated tumour not significantly
influenced by HIV-induced immunosuppression
M Melbyel, TR Cote", D West3, L Kessler4, RJ Biggar2 and the AIDS/Cancer Working Group'
'Danish Epidemiology Science Center, Statens Serum Institut, Copenhagen, Denmark; 2Viral Epidemiology Branch, Division of
Cancer Etiology, National Cancer Institute, Rockville, MD 20852, USA; 3San Francisco Cancer Registry, San Francisco, USA;
4Applied Research Branch, Division of Cancer Prevention and Control, National Cancer Institute, MD 20852, USA; SMembers of
the AIDS/Cancer Working Group (for each city or state, thefirst member listed isfrom the AIDS-registry and the secondfrom the
cancer registry. San Francisco (G Lemp, D West); California (J Singleton, J Young); Los Angeles (P Kerndt, D Deapen); San
Diego (M Ginzberg, H Anton-Culver); Florida (S Lieb, R Hopkins); Georgia (B Williams, J Lif); New Jersey (D Morgan, W
Parkin).
Summary We used a link between cancer (859 398 reports) and AIDS (50050 reports) registries in the United
States to study whether nasopharyngeal carcinoma (NPC) was increased in the population with AIDS. There
was no indication of a significantly increased risk up to or after the AIDS diagnosis, which argues against
progressively failing immunity being important in the development of this malignancy
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The risk of several types of cancers is increased in
immunosuppressive conditions. Of these, non-Hodgkin's
lymphoma is most consistently associated with a wide
spectrum of immunosuppressive conditions, whether of
congenital, iatogenic or HIV-associated origin. In particu-
lar, studies of therapeutic immunosuppressive conditions
have shown increased risks for squamous cell skin cancer
and soft tissue sarcomas, especially Kaposi's sarcoma, but
excesses of myeloid leukaemia, malignant melanoma,
anogenital cancer and hepatoma have also been reported
(Hoover and Fraumeni, 1973; Harwood et al., 1979; Kinlen
et al., 1979; Penn, 1986; Birkeland et al., 1995). Based on
present evidence, the distribution of neoplastic diseases
reported among HIV-induced immunosuppressed subjects
appears to fall into a similar pattern (Rabkin and Blattner,
1991).
Many of the tumours linked with immunosuppression
have been suspected to have a viral cause. One mechanism
might be the failure to eliminate cells proliferating under the
influence of virus replication. Whereas two potentially
Epstein-Barr virus (EBV) -associated neoplasms, Burkitt's
lymphoma and Hodgkin's disease, appears to be influenced
by HIV-induced immunosuppression (Rabkin and Blattner,
1991; Boiocchi et al., 1993; Boyle et al., 1993), little has been
reported on nasopharyngeal carcinoma, another EBV-
associated tumour (Zur Hausen et al., 1970: Raab-Traub,
1992). In the present study we took advantage of a
programme which links AIDS and cancer registries in nine
localities of the USA to study a potential influence of severe
and long-term immunosuppression on the development of
this tumour.
Materials and methods
AIDS and cancer registries were linked in California, Florida,
metropolitan Atlanta and New Jersey as described in detail
elsewhere (Melbye et al., 1994). The analysis was restricted to
people aged below 70 years and the periods in which both
registries were functioning.
The International Classification of Diseases for Oncology
(ICD-0) was used to define the codes for nasopharyngeal
carcinoma (topography code 147; histology codes 80103,
80323, 80413-33, 80513-23, 80703-63, 80823, 80943-53,
81203, 81223, 81313). We calculated the expected incidence of
nasopharyngeal cancers after AIDS diagnosis by multiplying
SEER (Surveillance, Epidemiology and End Results Pro-
gramme) age-specific incidence rates by the corresponding
person-years at risk after AIDS diagnosis. A person was at
risk until the occurrence of either cancer or death, and
censored at 2.25 years after the AIDS diagnosis, or when
cancer surveillance ended, whichever came first. This
restriction was applied to limit problems associated with
loss to follow-up (e.g. unregistered deaths or migration away
from a registration area after an AIDS diagnosis but before a
cancer diagnosis). The observed number of cases was then
compared with the expected number to give observed/
expected ratios (relative risk) and Poisson-distributed 95%
confidence interval (CI) (Breslow and Day, 1987) To estimate
the expected number of cancers that would have occurred
among HIV-infected persons who die before their AIDS
diagnosis, we used modifications of techniques previously
described in detail (Feldman et al., 1986; Melbye et al., 1994).
Results
The linkage analysis included 859 398 reports of cancer and
50 050 reports of AIDS. As shown in Table I, we found four
patients with a diagnosis of NPC within 5 years before their
AIDS diagnosis. Two were squamous cell carcinomas and
two lymphoepithelial carcinomas. Overall, the relative risk of
being diagnosed with NPC within 5 years before and up to
2.25 years after the AIDS diagnosis was 2.4 (95% CI 0.7-
6.2) (Table II). There was no indication of a significantly
increased risk up to or after the AIDS diagnosis.
Discussion
The diagnosis of AIDS is generally preceded by several years
of increasing immunodeficiency which makes this condition a
unique way to study the influence of long-term immunosup-
pression on cancer development. In contrast to certain states
of immune-impairment, AIDS is not the result of treatment
with immunosuppressive drugs that themselves might
influence cancer risk. Previous studies of viral-associated
cancers in HIV-infected subjects have documented a more
than 40 000-fold increased risk for Kaposi's sarcoma; an
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Table I Characteristics of the subjects identified in a linkage between AIDS and cancer registries in nine regions of the lUSA and diagnosed
with nasopharyngeal carcinoma (NPC)
Tumour Histological type Gender Age Race HIV risk group
N'PC Squamous cell Male 44 'White Gay bisexual man
carcinoma
NPC Squamous cell Male 31 Black Gay bisexual. IVDA
carcinoma
NPC Lymphoepithelial Male 35 Hispanic Gav bisexual. IVDA
carcinoma
NWC Lymphoepithelial Male 49 White Gay bisexual man
carcinoma
IVDA. Intravenous drug abuse.
Table H Relative risk (observed expected ratio) of nasophanmgeal carcinoma (NPC) in AIDS patients compared with population controls
matched for age. sex and race
Timefrom AIDS No. of cases Relative risk
Tumour diagnosis Observed Expected (995% CI)
NPC >2-5 years before 2 0.73 2.74 (0.33-9.89)
2->0 years before 2 0.62 3.21 (0.39-11.59)
0-2.25 vears after 0 0.29
Total 4 1.64 2.43 (0.66-6.22)
increased risk of between 160 and 700 for non-Hodgkins
lymphoma (Biggar et al.. 1994). and an 84-fold increased risk
of anal cancer (Melbye et al.. 1994). With respect to invasive
cervical cancer the risk has only been found to be modestly
increased (4-6-fold) (Cote et al.. 1993). However, this figure
might be influenced by intensive Pap smear screening in HIV-
positive women. The low relative risk might also reflect the
fact that women have only recently become infected with
HIV to any large extent. Certainly. HIV-infected women
appear to have a significantly increased risk of its precursor
lesions as shown in a number of recent case-control studies
(IARC. 1995). In addition, viral shedding of. for example.
EBV. cytomegalovirus and human papillomavirus (HIPV) has
been shown to increase substantially in HIV-immunosup-
pressed subjects. Cervical and anal intraepithelial lesions have
been associated with increased viral shedding of HPV (IARC.
1995). However. we note that the pattern of increased risk for
only selective cancers in AIDS patients argues against the
concept of general immune surveillance of all proliferations
as a defence mechanism for controlling cancer development.
Mismatched cases and missed linkages may have inflated
or lowered the observed rates in the present analysis.
However. in a validation study of our linkage method in
Los Angeles. all records linking AIDS and cancer diagnoses
were reviewed bv direct examination of the information at
each registry. Overall. only nine (0.3%) of 2 646 records were
incorrectly linked (D Deapen. personal communication). An
analysis of other cancers not suspected to be AIDS-associated
did not indicate significant underreporting in AIDS patients
compared with the general population.
In the present study we found a relative risk of 2.4 for
NPC in HIV-infected subjects who developed AIDS which.
however, was not significantly different from that in the
general population. Recently. a Nordic study was published
which analysed cancer risk after renal transplantation based
on 5 692 recipients treated during the period 1964-82. In this
study the risk for NPC was not increased (Birkeland et al..
1995, and H.H. Storm, Danish Cancer Registry, personal
communication). Thus, despite the molecular evidence for a
viral association with this tumour, it appears that failure of
immunity does not significantly affect its incidence.
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